While baseline levels of CX3CR1+ CD8+ T cells were not associated with outcome in two cohorts of NSCLC patients treated with chemoIO with αPD‐(L)1 agents (n = 65 cumulatively), the percentage change in the frequency of CX3CR1+ CD8+ T cells, which varied between 10% to 20% between studies, could distinguish patients with PR from those with SD/PD. This evidence concerns the gene CX3CR1 and non-small cell lung carcinoma.